Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ)
CNY 10.34
(-0.58%)
CNY 10.34
(-0.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 124.71 Million CNY | -91.36% |
| 2022 | 1.37 Billion CNY | 34.1% |
| 2021 | 867.67 Million CNY | -45.18% |
| 2020 | 1.67 Billion CNY | 0.5% |
| 2019 | 1.83 Billion CNY | 64.71% |
| 2018 | 1.12 Billion CNY | 240.08% |
| 2017 | 348.64 Million CNY | -53.09% |
| 2016 | 757.94 Million CNY | -15.62% |
| 2015 | 891.08 Million CNY | 82.14% |
| 2014 | 468.91 Million CNY | 18.62% |
| 2013 | 404.78 Million CNY | -20.25% |
| 2012 | 507.96 Million CNY | -30.19% |
| 2011 | 732.36 Million CNY | -48.97% |
| 2010 | 1.43 Billion CNY | 46.2% |
| 2009 | 981.77 Million CNY | 362.22% |
| 2008 | 211.51 Million CNY | 132.84% |
| 2007 | 89.57 Million CNY | 55.27% |
| 2006 | 60.63 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 159.9 Million CNY | 148.13% |
| 2024 Q3 | 162.84 Million CNY | -75.75% |
| 2024 Q2 | 757.84 Million CNY | 72.59% |
| 2023 Q4 | -747.4 Million CNY | -1927.13% |
| 2023 Q3 | 40.9 Million CNY | -73.57% |
| 2023 Q1 | 118.61 Million CNY | 31.44% |
| 2023 Q2 | 154.79 Million CNY | 30.5% |
| 2023 FY | - CNY | -91.36% |
| 2022 Q2 | 457.73 Million CNY | 61.82% |
| 2022 FY | - CNY | 34.1% |
| 2022 Q4 | 90.23 Million CNY | -70.34% |
| 2022 Q3 | 304.29 Million CNY | -33.52% |
| 2022 Q1 | 282.86 Million CNY | 486.86% |
| 2021 Q2 | 296.52 Million CNY | 29.94% |
| 2021 FY | - CNY | -45.18% |
| 2021 Q1 | 228.19 Million CNY | -63.55% |
| 2021 Q4 | 48.19 Million CNY | -75.93% |
| 2021 Q3 | 200.28 Million CNY | -32.46% |
| 2020 FY | - CNY | 0.5% |
| 2020 Q4 | 626.11 Million CNY | 214.78% |
| 2020 Q1 | 456.58 Million CNY | -29.64% |
| 2020 Q2 | 412.87 Million CNY | -9.57% |
| 2020 Q3 | 198.9 Million CNY | -51.82% |
| 2019 Q2 | 136.12 Million CNY | -78.42% |
| 2019 Q3 | 281.65 Million CNY | 106.91% |
| 2019 Q4 | 648.9 Million CNY | 130.39% |
| 2019 FY | - CNY | 64.71% |
| 2019 Q1 | 630.67 Million CNY | 120.24% |
| 2018 Q3 | 294.67 Million CNY | 38.37% |
| 2018 Q2 | 212.95 Million CNY | 65.4% |
| 2018 FY | - CNY | 240.08% |
| 2018 Q4 | 286.35 Million CNY | -2.82% |
| 2018 Q1 | 128.74 Million CNY | 49.29% |
| 2017 Q4 | 86.23 Million CNY | 41.76% |
| 2017 Q3 | 60.83 Million CNY | -20.73% |
| 2017 Q2 | 76.73 Million CNY | 9611.79% |
| 2017 Q1 | 790.17 Thousand CNY | -99.79% |
| 2017 FY | - CNY | -53.09% |
| 2016 Q2 | 217.39 Million CNY | 74.56% |
| 2016 FY | - CNY | -15.62% |
| 2016 Q1 | 124.54 Million CNY | -72.42% |
| 2016 Q3 | 26.03 Million CNY | -88.02% |
| 2016 Q4 | 372.87 Million CNY | 1331.99% |
| 2015 Q1 | 190.01 Million CNY | -31.66% |
| 2015 Q4 | 451.58 Million CNY | 615.62% |
| 2015 Q3 | 63.1 Million CNY | -67.34% |
| 2015 Q2 | 193.23 Million CNY | 1.7% |
| 2015 FY | - CNY | 82.14% |
| 2014 Q2 | 118.39 Million CNY | 321.89% |
| 2014 Q1 | 28.06 Million CNY | -85.99% |
| 2014 FY | - CNY | 18.62% |
| 2014 Q4 | 278.03 Million CNY | 102.96% |
| 2014 Q3 | 136.99 Million CNY | 15.71% |
| 2013 Q4 | 200.25 Million CNY | 2832.48% |
| 2013 Q3 | -7.32 Million CNY | -103.85% |
| 2013 Q1 | 109.34 Million CNY | 3.17% |
| 2013 Q2 | 190.52 Million CNY | 74.25% |
| 2013 FY | - CNY | -20.25% |
| 2012 Q1 | 154.88 Million CNY | -33.13% |
| 2012 Q2 | 119.42 Million CNY | -22.9% |
| 2012 Q3 | 110.08 Million CNY | -7.82% |
| 2012 Q4 | 105.98 Million CNY | -3.72% |
| 2012 FY | - CNY | -30.19% |
| 2011 Q3 | 125.56 Million CNY | -52.27% |
| 2011 Q4 | 231.62 Million CNY | 84.48% |
| 2011 FY | - CNY | -48.97% |
| 2011 Q1 | 153.69 Million CNY | -50.41% |
| 2011 Q2 | 263.05 Million CNY | 71.15% |
| 2010 Q4 | 309.91 Million CNY | -23.53% |
| 2010 Q1 | 305.46 Million CNY | -29.08% |
| 2010 FY | - CNY | 46.2% |
| 2010 Q2 | 401.46 Million CNY | 31.43% |
| 2010 Q3 | 405.29 Million CNY | 0.95% |
| 2009 Q3 | 215.14 Million CNY | 26.94% |
| 2009 Q1 | 159.38 Million CNY | 0.0% |
| 2009 FY | - CNY | 362.22% |
| 2009 Q4 | 430.68 Million CNY | 100.18% |
| 2009 Q2 | 169.48 Million CNY | 6.34% |
| 2008 FY | - CNY | 132.84% |
| 2007 FY | - CNY | 55.27% |
| 2006 FY | - CNY | 0.0% |